| LifeCode - COMPLEX A |
|
FORMS TO APPLY: - Nasal drops
INDICATIONS - Cerebral palsy - Traumatic brain injury - Chronic purulent otitis - Diseases of hearing and vision - Speech disorders
EFFICIENCY OF LifeCode – COMPLEX A In clinical practice: Experience with the LifeCode – COMPLEX A in the residual stage of infantile cerebral palsy (CP) and the late period of severe traumatic brain injury (TBI). A total of 10 children (9.5 -17 years) with cerebral palsy in the form of spastic diplegia (SD) and 4 children (7-13) years with the consequences (CCT). LifeCode – COMPLEX A prescribed to patients in the form of rectal suppositories for 10 days, 2 candles on the night, every other day. During the course of of LifeCode – COMPLEX A all patients continued the standard rehabilitation treatment. After the therapy course of LifeCode – COMPLEX A in the group of children with cerebral palsy positive trend was observed in 2 children with 1 level and 2 children with the III level of motor disorders. In children with a level of motor disorders first became possible on all fours, standing up, children first were based on the forearms and knees. In both cases, decreased expression of anti-tank rifles, as well as abnormal muscle synergies and synkineses. Accordingly, the observed decrease in severity of pathological motor stereotype. Improved manipulative activity of hands. Decreased oligobradikineziya. Dynamics of Modified Ashworth Scale and the Adductor Tone Rating was 1 point. In connection with the decrease of pathological symptoms, changes in status of patients after a therapy of LifeCode – COMPLEX A was estimated at 2 points. In 2 children with the III level of motor disorders after LifeCode – COMPLEX A therapy showed improvement of hand movements and an increase in the rate of executed movements, data evaluation of muscle tone by Modified Ashworth Scale and the Adductor Tone Rating without dynamics. In these cases, noted only improve the functionality within the original level, so changing the condition of patients after a LifeCode – COMPLEX A therapy was rated at 1 point. In the group of children with the consequences of TBI positive effect of the drug occurred in 2 children II-m level of motor disorders. Hypertonicity observed decrease in muscle and an increase in active movements in the less affected limbs, predominantly in the distal leg. In the less affected limbs improved the pace and coordination of movements performed. Reduced muscle tone by Modified Ashworth Scale - 1 point. In these cases also showed improvement of functional capabilities within the initial level of severity of motor disorders, ie changes in status 2 patients after a LifeCode – COMPLEX A therapy estimated at 1 point.
However, the positive effect of the drug in these patients was temporary and gradually regressed within 2 weeks. Thus after the LifeCode – COMPLEX A therapy improvements of neurological status were observed in 6 out of 14 children: 4 people with cerebral palsy and 2 people with the consequences of head injury. In all cases, positive dynamics was presented a decrease in severity of spastic tetraparesis, while in 2 children with severe diabetes was observed decrease in severity of pathological tonic reflexes and reduction of the pathological motor stereotype. There were no objective changes in other neurological symptoms were observed. Relatives of the children stated they had an increase in overall motor activity, improve motor coordination, reduced fatigability. Unexpected was the greatest act of therapeutic efficacy of LifeCode – COMPLEX A (rate - 10 days) in children with cerebral palsy, with more pronounced positive dynamics of clinical symptoms noted with severe motor disorders. The findings suggest high individual variability in the sensitivity of patients to LifeCode – COMPLEX A. Study of autoimmune responses (APRs) sera of patients to the various components of LifeCode – COMPLEX A obtained by electrophoretic separation of the drug also showed significant individual differences in baseline. It is shown that the components of LifeCode – COMPLEX A in various combinations may participate in the AIR, with the degree of participation has a clear individual differences. After the treatment course revealed the change of combinations of positive APRs to different components of LifeCode – COMPLEX A. It is known that APRs are links of the pathogenesis of degenerative and destructive processes of the brain tissue that occur with head trauma and cerebral palsy, including a late residual stage. May influence the ARI is one aspect of an individual positive effect of LifeCode – COMPLEX A. In 52 children with developmental disabilities neuropsychiatric features (disease terms cerebral palsy, hereditary diseases, chromosomal syndromes), which was carried out, along with the main treatment candles FSU, including 12 children - twice with an interval of three - four months. These 12 children constituted the group to study the effectiveness of the FSU and to identify the dynamics of development of higher mental functions, in particular, the speech functions. As a control group of children were also examined with static-motor delays and psychoverbal development, which drive away the candles. And a control group of children were divided into 2 age subgroups (from 1 to 2.5 years old - younger group and from 3 to 7 years old - the oldest group). Candles FSU imposed once on the night in the dose: children under 10 kg. weight - a candle, from 10 to 30 kg - two candles. For the younger children the main group during the treatment also notes the positive dynamics in the oral praxis: increased movements of the lips, tongue, children are more actively repeat articulation adults. In the speech praxis - in lepetnoy speech, a large number of new sounds, improved speech activity, improved verbal contact with others, appeared reflected speech. In the speech gnosis - children better understand speech in everyday life has become more stable verbal attention. For the older children the main group in the oral praxis: increased movement of the tongue, lips, stepped chewing, children become more active to repeat the circulation of adults: a speech breathing voice emerged long exhalation. In the speech praxis - in the spontaneous speech is often used common phrases, improved sound pronunciation, improved verbal activity, improved contact in others, intensified reflected speech. In the speech gnogize improved understanding of everyday speech and intonation, it has become more stable verbal attention, verbal memory improved. Comparative analysis of control and basic groups can be concluded that patients receiving positive trend observed in the development of higher mental functions. Comparing the dynamics of oral, verbal praxis and speech gnosiza children and control group during the treatment, you can cancel that the largest shifts are observed in the speech praxis, and, positive trends revealed in equally out of control, and from the main group improved sound pronunciation and general verbal activity . In oral praxis and gnosis speech more pronounced effect was observed in the study group, compared with controls. The mobility of the articulatory apparatus improved in 4 of 12 children of the main group, in 2 children returned to normal speech breathing, there was a recurrence of a silent articulation of adults. In the sphere of verbal gnosis in 3 children a core group improved verbal attention in 4 - have increased an impressive speech. Thus, the marked differences in the dynamics of language functions in children the main (with candles «LifeCode – COMPLEX A») and control groups of children the core group often noted positive developments in oral praxis and gnosis of the speech. These children have observed a large activation of the reflected speech, more children after treatment is easier to come into contact with others. Using the FSE in 220 patients with sensorineural hearing loss in the form of rectal suppositories (dose: 1 g. of the active product for 10 kg. patient's wight per day) with I-IY how badly the hearing at the age of 1 year to 65 years has a positive effect in 60-70% of cases . The greatest clinical effect observed in the presence of reversible changes in the structures of the auditory analyzer by stimulating receptors in the inner ear, synoptic conductivity and cerebral cortex. When I-II degree of hearing loss, improved hearing function are more significant and prolonged. In severe degrees of injury application FSE stabilizes the threshold of acoustic sensitivity, raises the possibility of hearing aids, promotes the development of speech, to promote social adaptation in children. The drug improves memory, has a beneficial effect on the course of concomitant diseases and conditions. FSU is a pathogenetic treatment for sensorineural hearing loss. FSU used in the treatment of 139 sick children, suffering from various forms of chronic purulent otitis media between the ages of 3 to 18 years with disease duration from 3 to 14 years, receiving their highest number (78.5%) fell ill in HGSO age from 1 to 3 years. The use of FSE in the mild form HGSO (mezotimpanite) in all patients achieved cessation of discharge from the ear and stable remission of the inflammatory process, thereby further these patients to tympanoplasty. When conservative treatment of 63 cases of children with mesotympanitis resulted in 92% of patients to normalize autonomic tone (Eyton and vegetative lability). Functional state of the auditory tube after applying BSS at mezotimpanite virtually returned to normal. Therefore, the donor BSS containing peptide regulators, is a highly effective conservative treatment of patients with HGSO. FSU in the form of intramuscular injections were used in 22 patients with various eye diseases (diabetic retinopathy, glaucoma, myopia of high to medium). In all cases a positive effect. There were no complications with other organs and systems, were not observed side effects. Increases efficiency, grasps the general condition even when concomitant severe diseases (diabetes mellitus, myocardial infarction, hypertension). The drug used by intramuscular injection daily for 3-7 days at the rate of 0.15 ml per 1 kg of body weight. In patients with diabetic retinopathy (10 patients) a week after treatment visual acuity improved in both eyes: left 10%, right at 5% in two weeks - on the left 20% right - 15% over baseline . In patients with glaucoma (5 patients), with indicators of intraocular pressure to 28-30 mm Hg. Art. at fields of view up to 10-15-20 on the fixation point after a course of treatment FSU indicators of visual fields in two weeks were 20-30-45. In patients with moderate myopia within 10 days after the start of treatment was an increase in visual acuity. The first experience of the FSU in children with symptoms of autism in the 3-5 age group was obtained at the Institute for experimental phonetics and speech pathology. The drug is used in 5 cases of children with typical signs of autism (hyperactivity, poor speech) at a dose of 1 Candle (1 g product) per 10 kg weight of the child per day every day for 30 days. The observations showed a reduction of emotional and physical activity, improve concentration and understanding of game situations, the assimilation of the rules of self-service, the disappearance of perverted manifestations. Thus, the total number of sick children with various pathologies that have received the FSU, is 452 children. Not a single case there has been complications, addiction to the drug. FSE was used as an independent means of treatment and in combination with traditional therapy adopted in clinical practice. Comparison of treatment outcomes with the use of FSE and without (control) favor the FSU, namely, the tool is not only pathogenetically justified (sensorineural hearing loss), but effectively accelerates healing, increases the quality of life, level of employment, medical and social rehabilitation, especially in children in the early stages of development. |